Although several studies have addressed the best cutoff to be used in this analysis (46, 48–52), there has not been a detailed investigation aimed at determining if a loss of (auto)antigen – BCR interaction, which could obviate or reduce transmission of ongoing survival signals to the leukemic B cell, is the feature that is most responsible for defining M-CLL patients with better clinical outcomes. Here, BCR is linked to B-cell chronic lymphocytic leukemia.